P402 Interstitial and granulomatous lung disease in inflammatory bowel disease patients

Abstract Background Granulomatous (GL) and interstitial lung disease (ILD) are rare respiratory disorders that have been associated with inflammatory bowel disease (IBD). Clinical presentation is polymorphic and aetiology is unclear. Methods This was European Crohn’s and colitis organisation (ECCO)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Crohn's and colitis 2018-01, Vol.12 (supplement_1), p.S308-S308
Hauptverfasser: Eliadou, E, Moleiro, J, Ribaldone, D G, Astegiano, M, Rothfuß, K, Taxonera, C, Verstockt, B, Ghalim, F, Carbonnel, F, Festa, S, Berrozpe, A, Maia, L, Savarino, E, Ellul, P, Zagorowicz, E, Vavricka, S, Calvo, M, Koutroubakis, I, Hoentjen, F, Fernández Salazar, L, Callela, F, Cañete Pizarro, F, Soufleris, K, Sonnenberg, E, Cavicchi, M, Fiorino, G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Granulomatous (GL) and interstitial lung disease (ILD) are rare respiratory disorders that have been associated with inflammatory bowel disease (IBD). Clinical presentation is polymorphic and aetiology is unclear. Methods This was European Crohn’s and colitis organisation (ECCO) retrospective observational study performed as part of CONFER project. A call to all ECCO members was made to report concomitant granulomatous or ILD and IBD cases. Clinical data were recorded in a standardised case report form. Results Twenty-two granulomatous lung disease patients were identified from 18 university hospitals, 17 males and 5 females with a mean age of 46 years (18–86); 17 patients with Crohn’s disease (CD) and five with ulcerative colitis (UC). In 19 patients IBD diagnosis preceded lung disease in a median time of 10.6 years (0–27). In three patients lung disease were diagnosed in a median time of 14 months (8–24) before IBD. Only four patients had active disease. Seven patients had drug-related granulomatous disease (sarcoidosis n = 4) and 14 had non-drug-related GL (primary sarcoidosis n = 7, fungal infection n = 2 and unspecified n = 5). Ten patients (45%) required hospitalisation but none required invasive ventilation. Fifteen of 22 patients received systemic steroids and causative drug was stopped in all patients. At further follow-up, 15 of 22 patients had no respiratory symptoms. Thirty-one patients with ILD were identified from 14 medical centres, 12 females and 19 males with mean age of 47 years (17–84); eight patients had CD, 22 had UC and one had indeterminate colitis. All patients had IBD diagnosis prior to ILD with a median time of 10.27 years (0.3–51). Eight patients had active disease. Eleven patients had non-drug-related ILD and 20 had drug-related ILD (mesalazine n = 9, methotrexate n = 1, golimumab n = 1, vedolizumab n = 1 and infliximab n = 8). ILD cases were classified as: Cryptogenic organising pneumonia n = 11, Eosinophilic pneumonitis n = 2, bronchiolitis n = 2, acute interstitial pneumonia n = 8, interstitial lung disease due to connective tissue n = 1, idiopathic fibrosis n = 6 and unclassified n = 1. Twenty-five patients (80.6%) required hospitalisation and one required non-invasive ventilation. Twenty-seven patients (87%) received systemic steroids and causative drug was stopped in all patients. At further follow-up, 14 of 31 patients had no respiratory symptoms, 7 of 31 had some improvement, and 4 of 31 had ongoing s
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjx180.529